Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Sigilon Therapeutics, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutic treatments for a wide range of chronic diseases. Its program includes Rare Blood Disorders, Lysosomal Storage Diseases, and Endocrine and Other Chronic Diseases. The company was founded by Daniel G. Anderson, Robert S. Langer Jr., Jose Oberholzer, Arturo Vegas, and Omid Veiseh on May 14, 2015 and is headquartered in Cambridge, MA.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.